1. Expression of Concern : Comparison of myo‐inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial
- Author
-
Fereshteh Bahmani, Fatemeh Foroozanfard, Pegah Farhat, Bita Badehnoosh, Zatollah Asemi, Hamidreza Jamilian, Esmat Aghadavod, Faraneh Afshar Ebrahimi, and Mehri Jamilian
- Subjects
medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,endocrine system diseases ,business.industry ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,medicine.disease ,Peripheral blood mononuclear cell ,Polycystic ovary ,law.invention ,Metformin ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Randomized controlled trial ,law ,Internal medicine ,medicine ,business ,Hyperinsulinism ,Testosterone ,medicine.drug ,Hormone - Abstract
SummaryObjective To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited. This study was carried out to compare myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with PCOS. Design, Patients and Measurements This randomized controlled trial was conducted among 60 subjects with PCOS aged 18-40 years. Subjects were randomly allocated into two groups to receive either myo-inositol (N=30) or metformin (N=30) for 12 weeks. Gene expression of inflammatory cytokines was assessed in peripheral blood mononuclear cells (PBMCs) of PCOS women by RT-PCR. Results After the 12-week intervention, compared with metformin, myo-inositol intake significantly decreased serum total testosterone (-1.4±4.2 vs. +0.7±1.4 nmol/l, P=0.03), modified Ferriman Gallwey (mF-G) scores (-1.1±0.7 vs. -0.5±0.8, P=0.01) and serum high-sensitivity C-reactive protein (hs-CRP) levels (-2.6±3.9 vs. +0.2±1.5 mg/L, P
- Published
- 2017